These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 1946835)

  • 41. Influences on cognitive heterogeneity in schizophrenia.
    Goldstein G; Shemansky WJ
    Schizophr Res; 1995 Dec; 18(1):59-69. PubMed ID: 8929762
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [The ego/self experience of schizophrenic patients].
    Scharfetter C
    Schweiz Arch Neurol Psychiatr (1985); 1995; 146(5):200-6. PubMed ID: 8658100
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Discrimination between and among schizophrenics and other pathologies using a Spanish version of the Whitaker Index of Schizophrenic Thinking.
    Godoy JF; Fernandez M; Muela JA; Roldan G; Catena A; Puente AE
    J Clin Psychol; 1994 Mar; 50(2):158-61. PubMed ID: 8014238
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Borderline personality subcategories.
    Andrulonis PA; Glueck BC; Stroebel CF; Vogel NG
    J Nerv Ment Dis; 1982 Nov; 170(11):670-9. PubMed ID: 7119767
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neurocognitive functioning as intermediary phenotype and predictor of psychosocial functioning across the psychosis continuum: studies in schizophrenia and bipolar disorder.
    Jabben N; Arts B; van Os J; Krabbendam L
    J Clin Psychiatry; 2010 Jun; 71(6):764-74. PubMed ID: 20122370
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Depression in borderline personality disorder: lifetime prevalence at interview and longitudinal course of symptoms.
    Perry JC
    Am J Psychiatry; 1985 Jan; 142(1):15-21. PubMed ID: 3871311
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation sensitivity as a moderator of communication disorder in schizophrenia.
    Grant PM; Beck AT
    Psychol Med; 2009 Jul; 39(7):1211-9. PubMed ID: 19379529
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Insight into neurocognitive dysfunction in schizophrenia.
    Medalia A; Thysen J
    Schizophr Bull; 2008 Nov; 34(6):1221-30. PubMed ID: 18199632
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Rorschach test and the positive and negative symptoms of schizophrenia].
    Basińska M; Rybakowski J
    Psychiatr Pol; 1991; 25(5):16-22. PubMed ID: 1821988
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anxiety symptoms in a major mood and schizophrenia spectrum disorders.
    Karpov B; Joffe G; Aaltonen K; Suvisaari J; Baryshnikov I; Näätänen P; Koivisto M; Melartin T; Oksanen J; Suominen K; Heikkinen M; Paunio T; Isometsä E
    Eur Psychiatry; 2016 Sep; 37():1-7. PubMed ID: 27447101
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Relationships among negative, positive, and depressive symptoms in schizophrenia and psychotic depression.
    Sax KW; Strakowski SM; Keck PE; Upadhyaya VH; West SA; McElroy SL
    Br J Psychiatry; 1996 Jan; 168(1):68-71. PubMed ID: 8770431
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of the neurocognitive profiles of individuals with elevated psychotic or depressive symptoms.
    Grossman M; Best MW; Harrison AG; Bowie CR
    Early Interv Psychiatry; 2019 Aug; 13(4):928-934. PubMed ID: 29968389
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Structured interview data on 102 cases of multiple personality disorder from four centers.
    Ross CA; Miller SD; Reagor P; Bjornson L; Fraser GA; Anderson G
    Am J Psychiatry; 1990 May; 147(5):596-601. PubMed ID: 2183634
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Attentional performance in patients with psychotic and nonpsychotic major depression and schizophrenia.
    Nelson EB; Sax KW; Strakowski SM
    Am J Psychiatry; 1998 Jan; 155(1):137-9. PubMed ID: 9433355
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Brief Psychiatric Rating Scale (BPRS) and the Nurses' Observation Scale for Inpatient Evaluation (NOSIE) in the evaluation of positive and negative symptoms.
    Dingemans PM
    J Clin Psychol; 1990 Mar; 46(2):168-74. PubMed ID: 2324299
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Self-mutilation, severity of borderline psychopathology, and the Rorschach.
    Baity MR; Blais MA; Hilsenroth MJ; Fowler JC; Padawer JR
    Bull Menninger Clin; 2009; 73(3):203-25. PubMed ID: 19807224
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neurocognitive function and insight in schizophrenia: support for an association with impairments in executive function but not with impairments in global function.
    Lysaker PH; Bell MD; Bryson G; Kaplan E
    Acta Psychiatr Scand; 1998 Apr; 97(4):297-301. PubMed ID: 9570491
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Correlates of cognitive impairment and depressive mood disorder in multiple sclerosis.
    Möller A; Wiedemann G; Rohde U; Backmund H; Sonntag A
    Acta Psychiatr Scand; 1994 Feb; 89(2):117-21. PubMed ID: 8178661
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The subsyndromal phenomenology of borderline personality disorder: a 10-year follow-up study.
    Zanarini MC; Frankenburg FR; Reich DB; Silk KR; Hudson JI; McSweeney LB
    Am J Psychiatry; 2007 Jun; 164(6):929-35. PubMed ID: 17541053
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Deficits in sustained attention in schizophrenia and affective disorders: stable versus state-dependent markers.
    Liu SK; Chiu CH; Chang CJ; Hwang TJ; Hwu HG; Chen WJ
    Am J Psychiatry; 2002 Jun; 159(6):975-82. PubMed ID: 12042186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.